The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
News|Articles|March 31, 2026
March Roundup of FDA Approvals in Oncology: 4 Decisions to Know
Author(s)Kristi Rosa
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in March 2026 spanning tumor types.
Advertisement
Advertisement
Below is your guide to all the oncologic options that were approved, rejected, or withdrawn by the FDA in March 2026. The regulatory roundup provides everything you need to know, right at your fingertips—all the topline data that supported the decisions and expert insights detailing clinical practice implications.
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
Lanreotide injection, a generic formulation referencing lanreotide, was approved by the FDA for GEP-NETs management.
The FDA granted final approval to Lutetium Lu 177 dotatate biosimilar for patients with SSTR-positive GEP-NETs.
The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Advertisement
Advertisement